['type 2 diabetes mellitus, ckd and albuminuria']
['dapagliflozin 10 mg', 'saxagliptin 2.5 mg', 'matching placebo for dapagliflozin 10 mg and saxagliptin 2.5mg']

        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Female or male aged ≥18 years

          -  History of type 2 diabetes mellitus for more than 12 months

          -  HbA1c≥7.0% and ≤11.0%

          -  Stable antidiabetic treatment during the last 12 weeks up to randomization

          -  eGFR 25-75 mL/minute/1.73m2, inclusive

          -  Micro or macroalbuminuria (UACR 30 - 3500 mg/g)

          -  Treatment with ACE inhibitor or an ARB for at least 3 months prior to screening

          -  Body mass index between 20 and 45 kg/m2

        Exclusion Criteria:

          -  Any of the following CV/Vascular Diseases within 3 month prior to signing the consent
             at Visit 1:

               -  Myocardial infarction

               -  cardiac surgery or revascularization (CABG/PTCA)

               -  unstable angina

               -  unstable HF

               -  New York Heart Association (NYHA) Class III-IV

               -  transient ischemic attack (TIA) or significant cerebrovascular disease

               -  unstable or previously undiagnosed arrhythmia

          -  Significant hepatic disease, including, but not limited to, chronic active hepatitis
             and/or severe hepatic insufficiency

          -  Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) > 3X ULN

          -  Total Bilirubin (TB) >2 mg/dL (34.2 μmol/L)

          -  History of acute kidney injury requiring renal replacement therapy (dialysis or
             ultrafiltration) or any biopsy or imaging verifying intercurrent kidney disease other
             than diabetic nephropathy or diabetic nephropathy with nephrosclerosis

          -  Ongoing treatment with a SGLT2 inhibitor, GLP-1 agonist or DPP4 inhibitors

          -  Any condition which, in the judgment of the Investigator, may render the patient
             unable to complete the study or which may pose a significant risk to the patient or
             patient suspected or with confirmed poor protocol or medication compliance
      